SCHEMBL6488906

SCHEMBL6488906

CCOC(=O)CCCOc1cc(C)c2nc(C)n(Cc3cc(Cl)ccc3Cl)c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
MCL1 Q07820 5/20 0.40
PLA2G2A P14555 3/20 0.40
CYSLTR2 Q9NS75 2/20 0.38
CYSLTR1 Q9Y271 2/20 0.38
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
P2RY12 Q9H244 1/20 0.38
BRD4 O60885 1/20 0.38
NPY1R P25929 1/20 0.38
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 2/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
HSD17B10 Q99714 1/20 0.37
BCL2L1 Q07817 1/20 0.37
USP2 O75604 1/20 0.36
DCTPP1 Q9H773 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6502915 0.93 SMN1; SMN2 (0.44) MEN1KMT2AMCL1PLA2G2ACYSLTR2
SCHEMBL6489154 0.90 ALDH1A1 (0.47) MCL1PLA2G2ACYSLTR2CYSLTR1PDE3B
SCHEMBL6501595 0.90 MCL1 (0.46) MCL1PLA2G2ABCL2L1DCTPP1
SCHEMBL6488241 0.86 MCL1 (0.43) KMT2AMCL1PLA2G2ACYSLTR2CYSLTR1
SCHEMBL6501772 0.86 PIK3C2B (0.47) MCL1PLA2G2ACYSLTR2CYSLTR1PDE3B
SCHEMBL6487797 0.86 PIK3C2B (0.46) MCL1PLA2G2ACYSLTR2CYSLTR1PDE3B
SCHEMBL6499832 0.86 PLA2G2A (0.42) MCL1PLA2G2ACYSLTR2CYSLTR1PDE3B
SCHEMBL6491512 0.86 MCL1 (0.41) MEN1KMT2AMCL1PLA2G2ACYSLTR2
SCHEMBL6488675 0.86 PLA2G2A (0.41) MEN1KMT2AMCL1PLA2G2ACYSLTR2
SCHEMBL6486770 0.85 MCL1 (0.40) MEN1KMT2AMCL1PLA2G2ACYSLTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD MEN1 1604/4885KMT2A 561/4885MCL1 806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.